News Sentiment

IDYA sentiment intelligence

Ideaya Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 36.99 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-1.8% over one week, +27.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Ideaya Biosciences chief accounting officer sells $382,130 in stock

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -1.8% Price digesting
Trend fit Trend inactive 27.6% over four weeks
Fair value 21.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 45
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingView 8
simplywall.st 5
MT Newswires 4
Investing.com 3
Quartr 3
PR Newswire 3

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 13
Analyst action 5
Regulatory and legal 4
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Investing.com Direct company coverage

Ideaya Biosciences chief accounting officer sells $382,130 in stock

Andres Ruiz Briseno, Chief Accounting Officer of IDEAYA Biosciences, sold 9,550 shares of the company's stock for approximately $382,130. The sale was carried out under a Rule 10b5-1 trading plan and occurred after an exercise of stock options. Despite the sale, the company maint

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 04:41
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com

This article reports on a Form 4 filing for Ideaya Biosciences Inc. dated July 9, 2026. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The content provided is minimal, simply stating the company, the form type, and the date.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 04:39
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com

Ideaya Biosciences' Chief Accounting Officer, Andres Ruiz Briseno, sold 9,550 shares totaling $382,130 on July 7, 2026, under a Rule 10b5-1 trading plan. This transaction occurred after he acquired the same number of shares through stock option exercise. Despite the sale occurrin

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 22:02
Source
Investing.com Nigeria
Stock Titan Direct company coverage

IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares

IDEAYA Biosciences' Chief Accounting Officer, Andres Ruiz Briseno, exercised 9,550 stock options at $12.86 per share and subsequently sold all 9,550 common shares at a weighted average price of $40.01 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan ad

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:10
Source
Stock Titan
Quartr Direct company coverage

IDEAYA Biosciences (IDYA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

IDEAYA Biosciences (IDYA) presented a summary of its 43rd Annual J.P. Morgan Healthcare Conference, highlighting multiple first-in-class programs and key clinical milestones. The company is advancing six programs in the clinic and targeting three new INDs for 2025, with significa

Tone
Positive 91/100
Event
Market update
Published
09 Jul 2026 04:39
Source
Quartr
Quartr Direct company coverage

IDEAYA Biosciences (IDYA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

IDEAYA Biosciences (IDYA) provided an update at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, highlighting the rapid enrollment in its Darovasertib trial for metastatic uveal melanoma, with potential for accelerated approval data readout by late next year. The com

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 04:39
Source
Quartr
Quartr Direct company coverage

IDEAYA Biosciences (IDYA) RBC Capital Markets Global Healthcare Conference 2025 summary

IDEAYA Biosciences anticipates a transformational year with four major data readouts for Darovasertib in uveal melanoma, including randomized PFS and OS data by year-end 2025, and plans to launch a registrational neoadjuvant study. The company aims for Accelerated Approval for Da

Tone
Positive 73/100
Event
Regulatory and legal
Published
08 Jul 2026 16:40
Source
Quartr
Simply Wall Street Direct company coverage

IDEAYA Biosciences (IDYA) Joins Russell Growth Benchmarks, Is The Stock Fully Priced?

IDEAYA Biosciences (IDYA) has been included in several Russell Growth Benchmarks, leading to increased investor interest and a 30-day stock return of 43.2%. While the company's Price-to-Sales (P/S) ratio of 17.1x appears high compared to industry averages and its estimated fair P

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 04:11
Source
Simply Wall Street
Stock Titan Direct company coverage

[144] IDEAYA Biosciences, Inc. SEC Filing

This article details an SEC Form 144 filing by IDEAYA Biosciences, Inc. (IDYA) concerning a proposed sale of securities. The document outlines the filer and issuer information, securities to be sold including common stock acquired through stock option exercise, and specifies J.P.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 04:09
Source
Stock Titan
Stock Traders Daily Direct company coverage

How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing

Ideaya Biosciences Inc. (IDYA) shows strong sentiment across all horizons, leading to an overweight bias. AI models have generated three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis indica

Tone
Positive 73/100
Event
Analyst action
Published
08 Jul 2026 03:10
Source
Stock Traders Daily
Investing.com South Africa Direct company coverage

Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com

Ideaya Biosciences Inc. (NASDAQ: IDYA) has reached a new 52-week high of $39.28, representing an 85.02% increase over the past year and bringing its market capitalization to $3.73 billion. Analysts have set a high price target of $66, reflecting strong investor confidence. The co

Tone
Positive 90/100
Event
Analyst action
Published
06 Jul 2026 15:40
Source
Investing.com South Africa
Investing.com Direct company coverage

Ideaya Biosciences stock hits 52-week high at $39.28

Ideaya Biosciences Inc. stock has reached a 52-week high of $39.28, reflecting an 85.02% increase over the past year and a market capitalization of $3.73 billion. This surge follows a successful public offering raising $345 million and the initiation of a Phase 1 clinical trial f

Tone
Positive 70/100
Event
Market update
Published
06 Jul 2026 15:39
Source
Investing.com
Simply Wall Street Direct company coverage

How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion

IDEAYA Biosciences (IDYA) has been added to several Russell growth and small-cap indexes, increasing its visibility to institutional investors. This inclusion, however, does not alter the core investment risk that depends on successful clinical and regulatory outcomes for its onc

Tone
Positive 63/100
Event
Regulatory and legal
Published
03 Jul 2026 14:39
Source
Simply Wall Street
Market source Direct company coverage

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences announced it granted non-qualified stock options for 98,000 shares to four new employees on June 25, 2026. These grants, made under the 2023 Employment Inducement Incentive Award Plan, are a material inducement for their employment, in compliance with Nasdaq Li

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 18:10
Source
Market source
marketscreener.com Direct company coverage

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark

IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 2500 Growth Benchmark. The company, an oncology firm focused on developing therapies for cancer, saw its stock price increase by 1.97%. IDEAYA Biosciences engages in the discovery, development, and commerciali

Tone
Positive 72/100
Event
Market update
Published
30 Jun 2026 13:11
Source
marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J

This article provides financial information for IDEAYA Biosciences, Inc. (FWB:30J) on TradingView, specifically focusing on its enterprise value to EBIT forward. It lists various general financial and community features available on the platform for this company's stock.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 01:09
Source
TradingView
www.marketscreener.com Direct company coverage

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark

IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), a company focused on oncology therapies, has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion highlights the company's growth trajectory and its position within the small-cap market. The article also provides an o

Tone
Positive 77/100
Event
Market update
Published
29 Jun 2026 20:40
Source
www.marketscreener.com
marketscreener.com Direct company coverage

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark

IDEAYA Biosciences, Inc. (NasdaqGS:IDYA) has been added to the Russell 3000E Growth Benchmark. This news, published on June 29, 2026, highlights the company's inclusion in a significant stock market index. IDEAYA Biosciences is a precision oncology company focused on developing t

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 13:11
Source
marketscreener.com
TradingView Direct company coverage

Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J

The article provides the "Price to sales forward" data for IDEAYA Biosciences, Inc. (FWB:30J) as listed on the Frankfurt Stock Exchange. It indicates that the market is closed and no trades have occurred for this specific financial metric. The data is available through TradingVie

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA

This article provides financial data for IDEAYA Biosciences, Inc. (IDYA) focusing on its price to book forward ratio. It highlights the company's listing on the Nasdaq Stock Market under the Pharmaceuticals: Major category within Health Technology. The content also includes vario

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:41
Source
TradingView
www.marketscreener.com Direct company coverage

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark

IDEAYA Biosciences, Inc. (NasdaqGS: IDYA) has been added to the Russell 2000 Growth Benchmark. The company, which specializes in oncology therapies, recently announced its CEO as Chairman of the Board and initiated a Phase 1/2 clinical study for pancreatic and lung cancers. This

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 10:40
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA

This article provides a brief mention of the "Enterprise value to EBIT forward" metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). It appears to be a stub or a section within a larger financial data platform like TradingView, designed to display key financial ratios for the comp

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA

This article focuses on the enterprise value to revenue forward metric for IDEAYA Biosciences, Inc. (NASDAQ: IDYA). The content presented is a financial data point from TradingView, indicating a key valuation multiple for the company.

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J

The article provides a financial metric for IDEAYA Biosciences, Inc. (FWB:30J), specifically its enterprise value to revenue forward. It notes that this data was "Made by humans" and that the market was closed with no trades at the time of publication. The content appears to be a

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 00:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J

This article focuses on the "Price to book forward" financial metric for IDEAYA Biosciences, Inc. (FWB:30J) on the Frankfurt Stock Exchange. It indicates no trades and a closed market at the time of publication. The page appears to be a financial data portal displaying an overvie

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 22:10
Source
TradingView